Video: Bio Farma Needs Seven Years to Produce Typhoid Fever Vaccine
Jakarta, CNBC Indonesia – Bio Farma, as the parent holding company of the pharmaceutical state-owned enterprises (SOEs), continues to strengthen the fundamentals and self-reliance of the national pharmaceutical industry through business transformation and financial restructuring.
President Director of Bio Farma, Shadiq Akasya, said the pharmaceutical SOEs are being restructured by creating an effective and efficient business scale, so that inefficient products are undergoing production ‘pruning’. In addition, the business model is being directed towards greater efficiency, as seen at Kimia Farma with its distribution chain down to Kimia Farma pharmacies, which can strengthen financial fundamentals. A number of companies within the pharmaceutical SOE group are also undergoing financial restructuring, including financing injections.
Specifically for Bio Farma, the pharmaceutical SOE holding company recently launched Bio-TCV (Typhoid Conjugate Vaccine), a conjugate typhoid vaccine developed domestically and the result of cooperation between Bio Farma and the International Vaccine Institute (IVI).
Source: jawawa.id (https://jawawa.id/newsitem/video-bio-farma-needs-seven-years-to-produce-typhoid-fever-vaccine-1788763942)
Originally published by CNBC Indonesia (https://www.cnbcindonesia.com/news/20260907123136-8-765752/video-produksi-vaksin-demam-tifoid-bio-farma-butuh-waktu-7-tahun), translated from Indonesian